A5033679949- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Blood Pressure and Hypertension Studies
- Underwater Vehicles and Communication Systems
- Cardiac Health and Mental Health
- Robotic Path Planning Algorithms
- Acute Ischemic Stroke Management
- Acute Myocardial Infarction Research
- Immune cells in cancer
- Cardiac Valve Diseases and Treatments
- Cytokine Signaling Pathways and Interactions
- Maritime Navigation and Safety
- Cardiac tumors and thrombi
- Cancer, Lipids, and Metabolism
- COVID-19 Clinical Research Studies
- Neonatal Health and Biochemistry
- Sepsis Diagnosis and Treatment
- Phytochemistry and Biological Activities
- Vascular Anomalies and Treatments
- Inflammatory mediators and NSAID effects
- Infective Endocarditis Diagnosis and Management
- Neuroinflammation and Neurodegeneration Mechanisms
- Helicobacter pylori-related gastroenterology studies
University of Michigan
2016-2025
Michigan Medicine
2017-2024
Michigan United
2024
Dalian Maritime University
2022-2023
Qingdao University
2022-2023
Dalian University of Technology
2023
Michigan Public Health Institute
2022
University Health System
2020
Affiliated Hospital of Hangzhou Normal University
2019
Xiaomi (China)
2017
It is unclear how many patients treated with a direct oral anticoagulant (DOAC) are using concomitant acetylsalicylic acid (ASA, or aspirin) and this affects clinical outcomes.To evaluate the frequency outcomes of prescription ASA DOAC therapy for atrial fibrillation (AF) venous thromboembolic disease (VTE).This registry-based cohort study took place at 4 anticoagulation clinics in Michigan from January 2015 to December 2019. Eligible participants were adults undergoing treatment AF VTE,...
Abstract Background Studies suggest that less than 4% of patients with pulmonary embolisms (PEs) are managed in the outpatient setting. Strong evidence and multiple guidelines support use Pulmonary Embolism Severity Index (PESI) for identification acute PE appropriate management. However, calculating PESI score can be inconvenient a busy emergency department (ED). To facilitate integration into ED workflow, we created 2023 Epic -compatible clinical decision tool automatically calculates...
For patients anticoagulated with direct oral anticoagulants (DOACs) or warfarin and on aspirin (ASA) for nonvalvular atrial fibrillation and/or venous thromboembolism, it is unclear if bleeding outcomes differ.
Background While direct oral anticoagulants (DOACs) may be viewed as simpler to manage then warfarin, they present their own unique management challenges resulting in frequent off-label dosing. It is unknown what extent dosing occurs when a patient started on DOAC versus later treatment. Objectives We aimed better characterize occurring and evaluate the effectiveness of prescribing oversight using registry-based intervention. Methods evaluated data from Michigan Anticoagulation Quality...
Objective . The spectrum of UDP-glucuronyl transferase A1 ( UGT1A1 ) variants in hereditary unconjugated hyperbilirubinemia varies markedly between different ethnic populations. This study evaluated the genotypes patients from southeastern China. Methods We enrolled 60 China (44 men and 16 women; age range: 3–76 years) with performed genetic analysis gene by direct sequencing. Results For Gilbert syndrome, 85% (47/55) harbored pathogenic <mml:math...
A high SAMe-TT 2 R score predicted poor warfarin control and adverse events among atrial fibrillation patients. However, the has not been well validated in venous thromboembolism (VTE) cohort of 1943 warfarin-treated patients with acute VTE was analyzed to correlate time therapeutic range (TTR) clinical events. TTR <60% more frequent a (>2) versus low (0–1) (63.4% vs 52.3%, p<0.0001). correlated increased overall (7.9 4.5 events/100 patient years, p=0.002), driven primarily by...
Direct oral anticoagulants (DOACs) have overtaken warfarin in the treatment of nonvalvular atrial fibrillation (AF) and venous thromboembolism (VTE). Limited data explore safety DOACs obesity.
Clinical factors and patient preferences are important for selecting oral anticoagulants venous thromboembolism (VTE) atrial fibrillation (AF). The relative association of sociodemographic with anticoagulant use is unknown. We evaluated a prospective cohort to compare variables in patients who continued on warfarin AF or VTE those transitioned 1 the direct (DOACs). Adult patients, newly started warfarin, were enrolled through 6 anticoagulation clinics across Michigan. Of 8468 53.3% had AF,...
This cohort study evaluates stroke and major bleeding rates before after switching from warfarin to a direct oral anticoagulant (DOAC) in patients grouped by pre-switch time-in-therapeutic range guideline thresholds.
BackgroundDifferences in clinical outcomes following a temporary interruption of warfarin or direct oral anticoagulant (DOAC) for surgical procedure are not well described. Differences patient characteristics from practice‐based cohorts have typically been accounted prior analyses.AimTo describe risk‐adjusted differences postoperative an vs DOACs.MethodsPatients receiving care at six anticoagulation clinics participating the Michigan Anticoagulation Quality Improvement Initiative were...
Background For more than a decade, guidelines have recommended limited 3 months of anticoagulation for the treatment provoked venous thromboembolism (VTE). How closely real-world practice follows guideline recommendations is not well described. Methods and Results In our multicenter, retrospective cohort study, we evaluated trends in duration patients enrolled MAQI2 (Michigan Anticoagulation Quality Improvement Initiative) registry who were receiving VTE. The comprises 6 centers Michigan...